A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Morning Overview on MSN
Math team solves cellular 'noise' puzzle, unlocking better treatments
Cells live in a world of chaos, constantly buffeted by random molecular jolts that can derail even the most carefully tuned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback